FCM
AVBP icon

Farallon Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Farallon Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-151,768
Closed -$2.71M – 187
2024
Q1 		$2.71M Buy
+151,768
New +$3.06M 0.01% 111

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Farallon Capital Management's AVBP Position: Q2 2024 in Review

Farallon Capital Management sold out of ArriVent BioPharma (AVBP) in Q2 2024, closing a stake of 151,768 shares — an estimated $2.71M sold.

Farallon Capital Management first reported a position in AVBP in Q1 2024 and held it in 1 quarter. The position peaked at $2.71M in Q1 2024. 54 funds tracked by Wall St. Rank hold AVBP as of Q2 2024.

  • Farallon Capital Management reported no remaining ArriVent BioPharma position as of Q2 2024 after selling out during the quarter.
  • Farallon Capital Management sold 151,768 ArriVent BioPharma shares in Q2 2024, an estimated $2.71M.
  • Farallon Capital Management first reported a position in ArriVent BioPharma in Q1 2024 and held it in 1 quarter.
  • Farallon Capital Management's ArriVent BioPharma position peaked at $2.71M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.